. 2014 Mar 26;6(3):727–738. doi: 10.4161/mabs.28591

Table 2. Affinities of TandAb, diabody and IgGs to different CD16 variants measured by SPR.

Construct	CD16A 158V					CD16A 158F					CD16B SH
Construct	k_{_on}	SE(k_{_on}₎	k_{_off}	SE(k_{_off}₎	K_D [nM]	k_{_on}	SE(k_{_on}₎	k_{_off}	SE(k_{_off}₎	K_D [nM]	k_{_on}	SE(k_{_on}₎	k_{_off}	SE(k_{_off}₎	K_D [nM]
CD30/CD16A TandAb	9.2E+04	1.4E+02	3.6E-05	4.8E-07	0.39	9.6E+04	1.8E+02	8.1E-05	6.0E-07	0.84	No binding	–	No binding	–	No binding
Fc-enhanced anti-CD30 IgG	4.3E+05	1.7E+02	0.0054	1.8E-04	13	3.2E+05	1.7E+04	0.0071	3.3E-04	22	1.1E+06	8.3E+04	0.013	9.6E-04	12
CD30/CD16A bispecific diabody	2.8E+05	3.6E+03	0.0097	2.4E-04	35	1.9E+05	2.5E+03	0.0080	8.8E-04	42	No binding	–	No binding	–	No binding
native IgG anti-CD30	9700	6.8E+02	0.0039	1.1E-04	400	1900	1.9E+02	0.0017	3.1E-04	890	1.1E+04	4.7E+02	0.0022	5.1E-05	200